Printed From:

Patient Satisfaction and Safety


SYNVISC has a demonstrated safety profile and high level of patient satisfaction

Based on a large, observational study to assess its tolerability and short-term effectiveness, SYNVISC has a demonstrated safety profile, and over 80% of patients were satisfied, rating it as a “good” or “very good” therapy at 3 weeks after the first injection1

of patients were satisfied with SYNVISC as their therapy at 3 weeks after the first injection1

Most commonly reported device-related AEs with SYNVISC1:

  • Pain in the injected knee
  • Swelling in the injected knee
  • Joint effusion

Potential AEs that may occur in association with intra-articular injection, including SYNVISC2:

  • Arthralgia
  • Injection-site pain
  • Joint stiffness
  • Arthritis
  • Joint swelling
  • Arthropathy
  • Joint warmth
  • Gait disturbance

References

  1. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269.
  2. SYNVISC [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.

Order Synvisc-One® and SYNVISC®

Learn about the different ordering options and how to get next-day delivery with your MySynviscONE® account.

Order now ›

SAUS.HYL.17.10.8155f(1)

Resources for
Your Patients

Share these tools to help patients get the most out of their treatment.

Resources for your patients
Browse Resources ›

SAUS.HYL.17.10.8155f(1)